Reinthaller A, Kainz C, Kohlberger P, Tempfer C, Gitsch G, Kölbl H, Breitenecker G
Abteilung für Gynäkologie und Geburtshilfe, Universitätsklinik für Frauenheilkunde, Wein, Osterreich.
Gynakol Geburtshilfliche Rundsch. 1995;35(1):16-9. doi: 10.1159/000272464.
Aberrant expression of specific isoforms of the cell adhesion molecule CD44 has been detected in various malignant human tumors. We wanted to verify whether the expression of these splice variants was associated with a higher incidence of metastasis and poor prognosis.
We studied the expression of CD44 splice variants v5, v6 and v7-8 by immunohistochemistry in human cervical cancer. 105 surgically treated patients with cervical cancer of stages IB-IIB were included in the study.
Tumors expressing exon v6 had significantly more often metastasized to the pelvic nodes (p = 0.04), and patients suffering from tumors expressing CD44v6 showed poorer overall survival. Even in cases with negative pelvic lymph nodes, we found a significantly poorer prognosis when tumors expressed CD44v6.
Among the investigated CD44 splice variants, expression of exons v6 and v7-8 is the most promising prognostic marker in cervical cancer. They can possibly identify patients with an increased risk earlier than morphologic prognostic parameters.
在多种人类恶性肿瘤中已检测到细胞粘附分子CD44特定亚型的异常表达。我们想验证这些剪接变体的表达是否与更高的转移发生率和不良预后相关。
我们通过免疫组织化学研究了CD44剪接变体v5、v6和v7 - 8在人类宫颈癌中的表达。105例接受手术治疗的IB - IIB期宫颈癌患者纳入本研究。
表达外显子v6的肿瘤转移至盆腔淋巴结的情况显著更常见(p = 0.04),且患有表达CD44v6肿瘤的患者总体生存率较差。即使在盆腔淋巴结阴性的病例中,我们发现当肿瘤表达CD44v6时预后也显著更差。
在所研究的CD44剪接变体中,外显子v6和v7 - 8的表达是宫颈癌中最有前景的预后标志物。它们可能比形态学预后参数更早地识别出风险增加的患者。